SCHEMBL18046007

SCHEMBL18046007

Cc1onc(-c2ccc(F)cc2)c1C(=O)Nc1ccccc1C=CC(=O)NO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 6/20 0.58
▸ GAA P10253 2/20 0.58
▸ KMT2A Q03164 4/20 0.53
▸ LMNA P02545 6/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ ALDH1A1 P00352 8/20 0.48
▸ KDM4E B2RXH2 4/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ CASP1 P29466 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ UBE2N P61088 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ HTT P42858 2/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ CRHBP P24387 1/20 0.47
▸ CRHR2 Q13324 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29608110 1.00 TSHR (0.58) TSHRGAAKMT2ALMNANPSR1
SCHEMBL18046004 1.00 TSHR (0.58) TSHRGAAKMT2ALMNANPSR1
SCHEMBL18046665 0.83 PTGS2 (0.61) TSHRGAAKMT2ALMNANPSR1
SCHEMBL29608448 0.83 PTGS2 (0.61) TSHRGAAKMT2ALMNANPSR1
SCHEMBL18046667 0.83 PTGS2 (0.61) TSHRGAAKMT2ALMNANPSR1
SCHEMBL18047041 0.82 ALDH1A1 (0.64) TSHRKMT2ALMNANPSR1MAPT
SCHEMBL29607145 0.82 ALDH1A1 (0.64) TSHRKMT2ALMNANPSR1MAPT
SCHEMBL18047039 0.82 ALDH1A1 (0.64) TSHRKMT2ALMNANPSR1MAPT
SCHEMBL8408128 0.73 ALDH1A1 (0.60) TSHRGAAKMT2ALMNAALDH1A1
SCHEMBL29161249 0.71 TSHR (0.53) TSHRGAAKMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO HEALTH, INC. (US) 2024-03-05 — — US claimed
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2022-03-10 — — US claimed
EP-3932914-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, Inc. (US) 2022-01-05 — — EP claimed
US-20180044282-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO EARLY DISCOVERY, INC. 2018-02-15 — — US claimed
EP-3268358-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Forma Therapeutics, Inc. (US) 2018-01-17 — — EP claimed
US-9745253-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2017-08-29 — — US claimed
WO-2016149099-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-09-22 — — WO claimed
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2016-09-15 — — US claimed
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO HEALTH, INC. (US) 2024-03-05 — — US disclosed
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2022-03-10 — — US disclosed
EP-3932914-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, Inc. (US) 2022-01-05 — — EP disclosed
US-10988441-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-27 — — US disclosed
US-20200331847-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2020-10-22 — — US disclosed
US-10508077-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-12-17 — — US disclosed
US-20180297939-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2018-10-18 — — US disclosed
US-20180044282-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO EARLY DISCOVERY, INC. 2018-02-15 — — US disclosed
EP-3268358-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Forma Therapeutics, Inc. (US) 2018-01-17 — — EP disclosed
US-9745253-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2017-08-29 — — US disclosed
WO-2016149099-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-09-22 — — WO disclosed
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044282-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-20200331847-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-10988441-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-10508077-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885
US-20180297939-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TSHR 4714/4885GAA 46/4885KMT2A 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback